U.S. Markets closed

Weakness seen in Genomic Health (GHDX): Stock Tumbles 9.0%

Zacks Equity Research

Genomic Health Inc. (GHDX) saw a big move last session, as the company’s shares fell nearly 9% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the most recent downtrend for GHDX, as the stock is down nearly 19% since Jan 22.

This medical research company has seen a flat track record when it comes to current year estimate revisions, as there has been no revision on either side over the past few weeks. The consensus for earnings estimate hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

GHDX currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the Medical Laboratories & Research industry include Affymetrix Inc. (AFFX), Cambrex Corporation. (CBM) and Idenix Pharmaceuticals Inc. (IDIX). While Cambrex holds a Zacks Rank #1 (Strong Buy), Affymetrix and Idenix Pharmaceuticals carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


GENOMIC HEALTH INC (GHDX): Free Stock Analysis Report

AFFYMETRIX INC (AFFX): Free Stock Analysis Report

CAMBREX CORP (CBM): Free Stock Analysis Report


Zacks Investment Research